Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.49 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.49 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GJA1 | P17302 | 1/20 | 0.45 |
| ▸ | GJB2 | P29033 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 3/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | AMY2A | P04746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6900928 | 1.00 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL2139671 | 1.00 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL2139680 | 1.00 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL1389240 | 1.00 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL15136505 | 0.97 | LGALS8 (0.53) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL16004719 | 0.88 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL7121167 | 0.88 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL5971913 | 0.88 | MEN1 (0.50) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL15844865 | 0.87 | AMY1A (0.52) | MEN1KMT2ALGALS8LGALS3LGALS4 | |
| SCHEMBL11776786 | 0.85 | LMNA (0.55) | MEN1KMT2AGJA1GJB2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059257-B1 | USE OF GLYCOLIPIDS AS ADJUVANTS | Helmholtz Zentrum für Infektionsforschung GmbH (DE) | 2016-03-16 | — | — | EP | claimed |
| US-8211463-B2 | Use of glycolipids as adjuvants | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2012-07-03 | — | — | US | claimed |
| US-20100015215-A1 | Use of Glycolipids as Adjuvants | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2010-01-21 | — | — | US | claimed |
| EP-2059257-A2 | USE OF GLYCOLIPIDS AS ADJUVANTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2009-05-20 | — | — | EP | claimed |
| WO-2008028667-A2 | USE OF GLYCOLIPIDS AS ADJUVANTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-03-13 | — | — | WO | claimed |
| EP-1897557-A1 | Use of glycolipids as adjuvants | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-03-12 | — | — | EP | claimed |
| EP-2059257-B1 | USE OF GLYCOLIPIDS AS ADJUVANTS | Helmholtz Zentrum für Infektionsforschung GmbH (DE) | 2016-03-16 | — | — | EP | disclosed |
| US-8211463-B2 | Use of glycolipids as adjuvants | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2012-07-03 | — | — | US | disclosed |
| US-20100015215-A1 | Use of Glycolipids as Adjuvants | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2010-01-21 | — | — | US | disclosed |
| EP-2059257-A2 | USE OF GLYCOLIPIDS AS ADJUVANTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008028667-A2 | USE OF GLYCOLIPIDS AS ADJUVANTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-03-13 | — | — | WO | disclosed |
| EP-1897557-A1 | Use of glycolipids as adjuvants | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100015215-A1 | Use of Glycolipids as Adjuvants | ENPP2, TLR5, SGMS1 | MEN1 732/4885KMT2A 2864/4885LGALS8 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.